Canada is first to approve IL-6 inhibitor sarilumab

Health Canada approved Kevzara sarilumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat moderately to severely active rheumatoid arthritis. The approval is the first in any country for the mAb against IL-6 receptor.

Specifically, Kevzara is indicated for adults who had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs)...